A population study by Stitziel et al. demonstrated a 34% reduced risk of CAD found among carriers of an ANGPTL3 loss-of-function (LOF) mutation compared to noncarriers (OR: 0.66; 95% CI: 0.44-0.98; p = 0.04). This evidence concerns the gene ANGPTL3 and coronary artery disorder.